Caution / the honest gap
CJC-1295 Side Effects in the Research Literature
Human safety data are limited to short pharmacokinetic studies. What the record shows, what it only flags as theoretical, and what it leaves blank.
What the Safety Record Does and Does Not Cover
The CJC-1295 side effects record is short, and its most important feature is what it lacks. Published human data are limited to early pharmacokinetic studies in healthy volunteers; there are no large or long-term safety trials of CJC-1295 in healthy adults [12]. CJC-1295 is not approved for human use anywhere [4].
That absence is the headline. Everything below is either a mechanistic expectation from GH/IGF-1 physiology or a documented regulatory concern — not a tally of adverse events from controlled trials, because that tally does not exist. We mark the difference at every line.
GH-Axis Effects: Fluid Retention and Insulin Sensitivity
Because CJC-1295 works by sustaining growth-hormone and IGF-1 elevation, the expected effects are the known effects of GH-axis stimulation. Growth hormone increases renal sodium reabsorption, which can cause fluid retention and edema, and GH affects insulin sensitivity [12]. These are mechanistic expectations carried over from GH physiology and from the broader GH-secretagogue literature; they are not adverse-event rates measured in a CJC-1295 safety trial. A study of GH and secretagogue effects on nitrogen balance and substrate metabolism informs the metabolic-effects profile of this kind of axis stimulation [10].
What are the side effects of CJC-1295?
GH-axis stimulation can cause fluid retention and edema (GH increases renal sodium reabsorption) and can affect insulin sensitivity [12]; sustained IGF-1 elevation carries a theoretical cancer-risk concern from epidemiology [12]. The FDA also cited immunogenicity [12]. Human safety data are limited to short PK studies — these are mechanistic and regulatory concerns, not measured trial event rates.
Sustained IGF-1 and the Cancer-Epidemiology Concern
The longer-horizon concern with any GH/IGF-1-raising compound is IGF-1 itself. Epidemiology links higher circulating IGF-1 to a modestly increased risk of certain cancers, which is why sustained IGF-1 elevation is treated as a theoretical safety question rather than a benign side effect [12]. CJC-1295 raised IGF-1 1.5- to 3-fold for nine to eleven days after a single dose and kept it above baseline up to 28 days after multiple doses [1] — exactly the kind of sustained elevation the epidemiologic concern is about. No study has connected CJC-1295 specifically to a cancer outcome; the concern is inferential, from the IGF-1 association.
The FDA Immunogenicity Flag and Regulatory Status
CJC-1295 is not approved by the FDA or any major regulator for human use; it is handled as a research chemical [4]. FDA briefing materials prepared for the 2024 Pharmacy Compounding Advisory Committee cited immunogenicity and other safety concerns for GH secretagogues including CJC-1295 [12]. The original long-acting DAC program (ConjuChem) was discontinued, and a Phase 2 trial in HIV-associated visceral obesity (NCT00267527) did not advance [12]. A patient death during the development era is sometimes cited in connection with the halted program, though a causal link to CJC-1295 was not established in the public record [12]. CJC-1295 is also prohibited at all times in sport under WADA Section S2 [4].
Quality and the Research-Supplier Problem
One category of risk is not pharmacological at all. CJC-1295 is sold by research suppliers whose product identity and purity are unverified, and the literature itself supplies the cautionary example: in 2010, analysts had to use mass spectrometry to identify CJC-1295 inside a seized preparation of unknown composition [6]. When the compound is not approved and not regulated as a drug, what is in a given vial is an open question.
Is CJC-1295 safe?
CJC-1295 is not approved for human use and has no large or long-term safety trials; published human data are limited to early PK studies [12]. Sustained GH/IGF-1 elevation raises theoretical concerns — fluid retention, insulin-sensitivity effects, the IGF-1/cancer epidemiology — and FDA briefing materials cited immunogenicity [12]. Safety is not established.
Are CJC-1295 peptides safe?
Safety is not established. CJC-1295 is unapproved with no long-term human trials; reported and theoretical concerns include fluid retention, insulin-sensitivity effects, the IGF-1/cancer epidemiologic signal, and immunogenicity flagged by the FDA [12]. Product quality from research suppliers is also unverified [6].
Does CJC-1295 affect testosterone?
CJC-1295 acts on the GH/IGF-1 axis, not the gonadal axis; it is not a testosterone-raising agent, and the published research does not characterize a direct testosterone effect [12]. Claims that it raises or lowers testosterone are not supported by the peer-reviewed CJC-1295 literature.
What to expect when taking CJC-1295?
In the human PK literature, single doses raised GH and IGF-1 for days while preserving GH pulsatility [1][3]. This page describes measured research outcomes only — it does not promise results, and CJC-1295 is not approved for human use [4].